These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 33087358)

  • 21. Large-scale proteomic analysis of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation.
    Johnson ECB; Dammer EB; Duong DM; Ping L; Zhou M; Yin L; Higginbotham LA; Guajardo A; White B; Troncoso JC; Thambisetty M; Montine TJ; Lee EB; Trojanowski JQ; Beach TG; Reiman EM; Haroutunian V; Wang M; Schadt E; Zhang B; Dickson DW; Ertekin-Taner N; Golde TE; Petyuk VA; De Jager PL; Bennett DA; Wingo TS; Rangaraju S; Hajjar I; Shulman JM; Lah JJ; Levey AI; Seyfried NT
    Nat Med; 2020 May; 26(5):769-780. PubMed ID: 32284590
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oxidative signature of cerebrospinal fluid from mild cognitive impairment and Alzheimer disease patients.
    Di Domenico F; Pupo G; Giraldo E; Badìa MC; Monllor P; Lloret A; Schininà ME; Giorgi A; Cini C; Tramutola A; Butterfield DA; Viña J; Perluigi M
    Free Radic Biol Med; 2016 Feb; 91():1-9. PubMed ID: 26675344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted mass spectrometry to quantify brain-derived cerebrospinal fluid biomarkers in Alzheimer's disease.
    Zhou M; Haque RU; Dammer EB; Duong DM; Ping L; Johnson ECB; Lah JJ; Levey AI; Seyfried NT
    Clin Proteomics; 2020; 17():19. PubMed ID: 32514259
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluid.
    Harari O; Cruchaga C; Kauwe JS; Ainscough BJ; Bales K; Pickering EH; Bertelsen S; Fagan AM; Holtzman DM; Morris JC; Goate AM;
    Biol Psychiatry; 2014 May; 75(9):723-31. PubMed ID: 24548642
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Integrated proteomics and network analysis identifies protein hubs and network alterations in Alzheimer's disease.
    Zhang Q; Ma C; Gearing M; Wang PG; Chin LS; Li L
    Acta Neuropathol Commun; 2018 Mar; 6(1):19. PubMed ID: 29490708
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A protein panel in cerebrospinal fluid for diagnostic and predictive assessment of Alzheimer's disease.
    Haque R; Watson CM; Liu J; Carter EK; Duong DM; Lah JJ; Wingo AP; Roberts BR; Johnson ECB; Saykin AJ; Shaw LM; Seyfried NT; Wingo TS; Levey AI
    Sci Transl Med; 2023 Sep; 15(712):eadg4122. PubMed ID: 37672565
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteomic analysis of cerebrospinal fluid in Alzheimer's disease: wanted dead or alive.
    Oláh Z; Kálmán J; Tóth ME; Zvara Á; Sántha M; Ivitz E; Janka Z; Pákáski M
    J Alzheimers Dis; 2015; 44(4):1303-12. PubMed ID: 25428253
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression.
    Wisch JK; Butt OH; Gordon BA; Schindler SE; Fagan AM; Henson RL; Yang C; Boerwinkle AH; Benzinger TLS; Holtzman DM; Morris JC; Cruchaga C; Ances BM
    Brain; 2023 Jul; 146(7):2944-2956. PubMed ID: 36542469
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids.
    Korecka M; Shaw LM
    J Neurochem; 2021 Oct; 159(2):211-233. PubMed ID: 34244999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L; Wojcik J; Núñez Galindo A; Corthésy J; Cominetti O; Oikonomidi A; Henry H; Migliavacca E; Bowman GL; Popp J
    J Alzheimers Dis; 2017; 60(4):1641-1652. PubMed ID: 29125490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.
    Visser PJ; Reus LM; Gobom J; Jansen I; Dicks E; van der Lee SJ; Tsolaki M; Verhey FRJ; Popp J; Martinez-Lage P; Vandenberghe R; Lleó A; Molinuevo JL; Engelborghs S; Freund-Levi Y; Froelich L; Sleegers K; Dobricic V; Lovestone S; Streffer J; Vos SJB; Bos I; ; Smit AB; Blennow K; Scheltens P; Teunissen CE; Bertram L; Zetterberg H; Tijms BM
    Mol Neurodegener; 2022 Mar; 17(1):27. PubMed ID: 35346299
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CSF profiling of the human brain enriched proteome reveals associations of neuromodulin and neurogranin to Alzheimer's disease.
    Remnestål J; Just D; Mitsios N; Fredolini C; Mulder J; Schwenk JM; Uhlén M; Kultima K; Ingelsson M; Kilander L; Lannfelt L; Svenningsson P; Nellgård B; Zetterberg H; Blennow K; Nilsson P; Häggmark-Månberg A
    Proteomics Clin Appl; 2016 Dec; 10(12):1242-1253. PubMed ID: 27604409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers.
    Khoonsari PE; Shevchenko G; Herman S; Remnestål J; Giedraitis V; Brundin R; Degerman Gunnarsson M; Kilander L; Zetterberg H; Nilsson P; Lannfelt L; Ingelsson M; Kultima K
    J Alzheimers Dis; 2019; 67(2):639-651. PubMed ID: 30614806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects.
    Maarouf CL; Andacht TM; Kokjohn TA; Castaño EM; Sue LI; Beach TG; Roher AE
    Curr Alzheimer Res; 2009 Aug; 6(4):399-406. PubMed ID: 19689240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Integrated Proteomics to Understand the Role of Neuritin (NRN1) as a Mediator of Cognitive Resilience to Alzheimer's Disease.
    Hurst C; Pugh DA; Abreha MH; Duong DM; Dammer EB; Bennett DA; Herskowitz JH; Seyfried NT
    Mol Cell Proteomics; 2023 May; 22(5):100542. PubMed ID: 37024090
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds.
    Remnestål J; Bergström S; Olofsson J; Sjöstedt E; Uhlén M; Blennow K; Zetterberg H; Zettergren A; Kern S; Skoog I; Nilsson P; Månberg A
    Alzheimers Res Ther; 2021 Mar; 13(1):54. PubMed ID: 33653397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alzheimer disease pathology and the cerebrospinal fluid proteome.
    Dayon L; Núñez Galindo A; Wojcik J; Cominetti O; Corthésy J; Oikonomidi A; Henry H; Kussmann M; Migliavacca E; Severin I; Bowman GL; Popp J
    Alzheimers Res Ther; 2018 Jul; 10(1):66. PubMed ID: 30021611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteome studies of CSF in AD patients.
    Davidsson P; Sjögren M
    Mech Ageing Dev; 2006 Feb; 127(2):133-7. PubMed ID: 16293296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease.
    Hampel H; Bürger K; Teipel SJ; Bokde AL; Zetterberg H; Blennow K
    Alzheimers Dement; 2008 Jan; 4(1):38-48. PubMed ID: 18631949
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset.
    Chiasserini D; van Weering JR; Piersma SR; Pham TV; Malekzadeh A; Teunissen CE; de Wit H; Jiménez CR
    J Proteomics; 2014 Jun; 106():191-204. PubMed ID: 24769233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.